Pharmacogenetics of Cyclophosphamide in Cancer Treatment

Cyclophosphamide is a widely used alkylating agent that requires metabolic conversion to exert its antineoplastic effects. As a prodrug, it undergoes hepatic bioactivation predominantly via cytochrome P450 enzymes, notably CYP2B6, to generate the cytotoxic metabolite phosphoramide mustard. Genetic polymorphisms in enzymes mediating both activation and detoxification pathways contribute to the marked interindividual variability in drug exposure, therapeutic efficacy and risk of adverse events. Variants in genes encoding cytochrome P450 oxidoreductase and glutathione S-transferases further modulate metabolism, while clinical factors such as age, sex and comorbidities influence pharmacokinetic profiles. Recent advances have elucidated the dual role of cyclophosphamide in cytotoxicity and immunomodulation, including depletion of regulatory T cells and interactions with the gut microbiome. Emerging oxazaphosphorine analogues and combination regimens with targeted agents seek to optimise the balance between efficacy and toxicity. The global burden of cancer and the continued reliance on cyclophosphamide across adult, paediatric and transplant settings underline the importance of integrating pharmacogenetic insights into dose individualisation and risk stratification.

Research from Nature Portfolio

A study in paediatric neuroblastoma patients examined the impact of CYP2B6 and CYP2C19 metaboliser phenotypes on treatment outcomes and toxicity. It demonstrated a clear association between CYP2B6 variants and haematological adverse events, including lymphopenia and thrombocytopenia, but not with urotoxicity. Younger age and female sex emerged as independent prognostic factors. These findings underscore the potential utility of genotype-guided dosing strategies to mitigate toxicity without compromising anti-tumour activity.

Pharmacogenetics of Cyclophosphamide in Cancer Treatment publication trend

The graph below shows the total number of articles in pharmacogenetics of cyclophosphamide in cancer treatment across all publications each year (not limited to Nature Index journals).

Technical terms

Pharmacogenetics: The study of how genetic variation affects individual responses to drugs.

Prodrug: An inactive compound that is metabolised in the body to produce an active drug.

Bioactivation: The enzymatic conversion of a prodrug into its pharmacologically active form.

Cytochrome P450 (CYP): A family of liver enzymes responsible for drug metabolism and biotransformation.

Genetic polymorphism: A variation in DNA sequence that can affect enzyme function and drug response.

AUC (area under the curve): A measure of total drug exposure over time.

Haploidentical HSCT: Stem cell transplantation using a donor mismatched at one human leukocyte antigen haplotype.

Graft-versus-host disease (GVHD): An immune-mediated complication in which donor cells attack recipient tissues.

References

1. Association between CYP2B6 genetic variability and cyclophosphamide therapy in pediatric patients with neuroblastoma. Scientific Reports (2023).
2. Cyclophosphamide Pharmacogenomic Variation in Cancer Treatment and Its Effect on Bioactivation and Pharmacokinetics. Advances in Pharmacological and Pharmaceutical Sciences (2024).
3. Cytochrome P450 Oxidoreductase Influences CYP2B6 Activity in Cyclophosphamide Bioactivation. PLOS ONE (2015).
4. Glutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with Cyclophosphamide. PLOS ONE (2016).
5. Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation. Frontiers in Immunology (2022).
6. Population Pharmacokinetic, Pharmacogenetic, and Pharmacodynamic Analysis of Cyclophosphamide in Ethiopian Breast Cancer Patients. Frontiers in Pharmacology (2020).